Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

This study has been completed.

First Received: July 12, 2002 Last Updated: September 28, 2007 History of Changes

Sponsored by:	Bristol-Myers Squibb
Information provided by:	Bristol-Myers Squibb
ClinicalTrials.gov Identifier:	NCT00041678

Purpose

The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.

Condition	Intervention	Phase
Alzheimer Disease	Drug: aripiprazole	Phase III

Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer's Disease Dementia Psychotic Disorders

Drug Information available for: Aripiprazole

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Eligibility

Ages Eligible for Study:	55 Years to 95 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria: - Institutionalized patients with Alzheimer's Disease

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00041678

Locations

United States, California
Local Institution
Rosemead, California, United States
United States, Florida
Local Institution
Miami, Florida, United States
United States, Tennessee
Local Institution
Nashville, Tennessee, United States
United States, Vermont
Local Institution
Bennington, Vermont, United States
Local Institution
Burlington, Vermont, United States
United States, Wisconsin
Local Institution
Milwaukee, Wisconsin, United States

Sponsors and Collaborators

Bristol-Myers Squibb

More Information

Additional Information:

BMS Clinical Trials Disclosure This link exits the ClinicalTrials.gov site

For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm This link exits the ClinicalTrials.gov site

No publications provided

Study ID Numbers:	CN138-005
Study First Received:	July 12, 2002
Last Updated:	September 28, 2007
ClinicalTrials.gov Identifier:	NCT00041678 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Bristol-Myers Squibb:

Psychosis Associated with Dementia of the Alzheimer's Type

Study placed in the following topic categories:

Tranquilizing Agents
Alzheimer Disease
Psychotropic Drugs
Central Nervous System Depressants
Central Nervous System Diseases
Brain Diseases
Neurodegenerative Diseases
Antipsychotic Agents

Cognition Disorders
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Psychotic Disorders
Aripiprazole
Dementia
Delirium

Additional relevant MeSH terms:

Tranquilizing Agents
Physiological Effects of Drugs
Alzheimer Disease
Nervous System Diseases
Psychotropic Drugs
Central Nervous System Diseases
Central Nervous System Depressants
Brain Diseases
Neurodegenerative Diseases

Antipsychotic Agents
Pharmacologic Actions
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Therapeutic Uses
Aripiprazole
Dementia
Tauopathies
Central Nervous System Agents

ClinicalTrials.gov processed this record on May 07, 2009